63430-96-6

Usage

Uses

Used in Medicinal Chemistry:
2-hydroxyMethyl-1,2,3,4-tetrahydroquinoline is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a promising candidate for the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Drug Development:
In the pharmaceutical industry, 2-hydroxyMethyl-1,2,3,4-tetrahydroquinoline serves as a building block for creating novel therapeutic agents. Its chemical properties make it suitable for the design of molecules with potential medicinal applications, such as antimicrobial, antiviral, or anticancer agents.
Used in Materials Science:
Due to its distinctive molecular structure, 2-hydroxyMethyl-1,2,3,4-tetrahydroquinoline may also find applications in the field of materials science. Its properties could be harnessed to develop new materials with specific characteristics, such as improved conductivity, stability, or reactivity.
Further research is necessary to fully explore and understand the potential uses and effects of 2-hydroxyMethyl-1,2,3,4-tetrahydroquinoline in these and other areas. Its unique structure and properties hold promise for future advancements in both medicinal and material sciences.

Upstream product

• 91-63-4 2-methylquinoline 
• 5470-96-2 quinoline 2-carbaldehyde 
• 24544-04-5 2,6-diisopropylbenzenamine 
• 62-53-3 aniline 

Downstream Products

• 618113-62-5 2-Iodomethyl-1,2,3,4-tetrahydro-quinoline 
• 1018826-75-9 (1-(4-methoxy-2,6-dimethylphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-2-yl)methanol 
• 497959-05-4 carbonic acid 1-(4-chloro-benzenesulfonyl)-1,2,3,4-tetrahydro-quinolin-2-ylmethyl ester 4-nitro-phenyl ester 

Relevant academic research and scientific papers

Consecutive Intermolecular Reductive Amination/Asymmetric Hydrogenation: Facile Access to Sterically Tunable Chiral Vicinal Diamines and N-Heterocyclic Carbenes

A highly enantioselective iridium- or ruthenium-catalyzed intermolecular reductive amination/asymmetric hydrogenation relay with 2-quinoline aldehydes and aromatic amines has been developed. A broad range of sterically tunable chiral N,N′-diaryl vicinal diamines were obtained in high yields (up to 95 %) with excellent enantioselectivity (up to >99 % ee). The resulting chiral diamines could be readily transformed into sterically hindered chiral N-heterocyclic carbene (NHC) precursors, which are otherwise difficult to access. The usefulness of this synthetic approach was further demonstrated by the successful application of one of the chiral vicinal diamines and chiral NHC ligands in a transition-metal-catalyzed asymmetric Suzuki–Miyaura cross-coupling reaction and asymmetric ring-opening cross-metathesis, respectively.

Tricyclic quinoxalinediones

Tricyclic quinoxalinediones of the formula: STR1 wherein X is alkyl, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, etc.; R 1 is H, etc.; R 2 is H, alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkylalkyl, arylalkyl, substituted arylalkyl, aryl, or substituted aryl; W is H, CO 2 R 3, CO 2 Y, CONR 3 R 4, CONR 3 Y, CON(OR 3)R 4, COR 3, CN, tetrazolyl, or substituted alkyl; R 3 and R 4 independently are H, alkyl, cycloalkyl, alkenyl, alkynyl, etc.; Y is mono-substituted alkyl or di-substituted alkyl; and n is an integer 0 or 1, or a pharmaceutically acceptable salt thereof, which are useful as a selective antagonist of glutamate receptor for the treatment or prevention of various diseases in animals including human being, for example, minimizing damage of central nervous system induced by ischaemic or hypoxylic conditions, treatment and/or prevention of neurodegenerative disorders, and further analgesics, antidepressants, anxiolitics, and anti-schizophrenics.